Study of Combination Ibrutinib and Venetoclax in Mantle Cell Lymphoma
The study includes patients with relapsed/refractory and treatment-naïve mantle cell lymphoma.
Diagnosis & Disease Information
SYMPATICO Trial: Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma
Researchers are seeking to compare the efficacy and safety of the combination of ibrutinib and venetoclax compared with ibrutinib and placebo in patients with mantle cell lymphoma.
Trial Compares LOXO-305 With Investigator’s Choice of BTK Inhibitors in Previously Treated MCL
The trial will compare LOXO-305 to investigator’s choice of ibrutinib, acalabrutinib, or zanubrutinib.
Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab
Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.
Mantle Cell Lymphoma: Analysis Reveals Real-World Patient Experiences With Ibrutinib
A retrospective analysis highlights the reasons for discontinuation of ibrutinib among patients with mantle cell lymphoma.
Obinutuzumab With Cytarabine Induction for Transplant-Eligible Mantle Cell Lymphoma
In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.
- Loading...
Loading...
Loading... 
Loading...